AbbVie Initiates Phase 3 Clinical Trial of IL-1α/β Bispecific Antibody Lutikizumab for Hidradenitis Suppurativa

▎Armstrong

On June 21, 2024, AbbVie registered a Phase III clinical trial on Clinicaltrials.gov for the IL-1α/β antibody Lutikizumab in the treatment of Hidradenitis Suppurativa.

This Phase III clinical trial plans to enroll 1,280 patients with hidradenitis suppurativa and is expected to be completed by the end of 2026.

In January this year, AbbVie announced the excellent phase II clinical data of Lutikizumab in the treatment of hidradenitis suppurativa.

Summary

KiniksArcalyst, a's IL-1α/β inhibitor, has been approved for marketing in the United States for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) and Deficiency of the Interleukin-1 Receptor Antagonist (DIRA). Huadong Medicine acquired the rights to this product in the Asia-Pacific region in February 2022.Benefits (including China, South Korea, Australia, and 18 other countries, but excluding Japan).